¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"dominant lethal trait"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mean lethal dose
    1. Æò±ÕÄ¡»ç¿ë·® 2. Æò±ÕÄ¡»ç¼±·®
  • median lethal dose
    1. Áß°£Ä¡»ç¿ë·® 2. Áß°£Ä¡»ç¼±·®
  • autosomal dominant disorder
    º¸Åë¿°»öü¿ì¼ºÁúȯ
  • dominant
    1. ¿ì¼º- 2. ¿ì¼¼-, ¿ìÀ§- 3. ¿ì¼º
  • dominant character
    ¿ì¼ºÇüÁú
  • dominant complement
    ¿ì¼ºº¸Ã¼
  • dominant eye
    ¿ì¼¼¾È
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
  • dominant hemisphere
    ¿ì¼º´ë³ú¹Ý±¸
  • dominant inheritance
    ¿ì¼ºÀ¯Àü
  • dominant mutation
    ¿ì¼ºµ¹¿¬º¯ÀÌ
  • dominant receptor
    ¿ì¼º¼ö¿ëü
  • homozygous dominant
    µ¿Á¾Á¢Çտ켺-
  • incompletely dominant
    ºÒ¿ÏÀü¿ì¼º-
  • sex-linked dominant inheritance
    ¼º¿¬°ü¿ì¼ºÀ¯Àü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ
  • lethal midline granuloma
    Ä¡»çÁ߽ɼ±À°¾ÆÁ¾
  • lethal
    Ä¡»ç-
  • lethal toxin
    Ä¡»çµ¶¼Ò
  • lethal titer test
    Ä¡»çÁ¤·®°Ë»ç
  • autosomal dominant disorder
    º¸Åë¿°»öü¿ì¼ºÁúȯ
  • dominant character
    ¿ì¼ºÇüÁú, Áö¹èÀûÇüÁú
  • dominant complement
    ¿ì¼ºµµ¿òü
  • dominant
    ¿ì¼º-, ¿ì¼¼-, ¿ìÀ§-, ¿ì¼º
  • dominant eye
    ¿ì¼¼¾È
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
  • dominant hemisphere
    ¿ì¼º´ë³ú¹Ý±¸
  • dominant inheritance
    ¿ì¼ºÀ¯Àü
  • dominant mutation
    ¿ì¼ºµ¹¿¬º¯ÀÌ
  • dominant receptor
    ¿ì¼º¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • sickle cell trait
    ÀûÇ÷±¸°â»óÇü¼º°æÇâ(îåúìϹÌÇßÒû¡à÷ÌËú¾)
  • thalassemia trait
    ÁöÁßÇØºóÇ÷¼ÒÁú(áÈòõ)
  • thalassemia trait
    #NAME?
  • trait(s)
    Ư¼º(÷åàõ), ¼ÒÁú(áÈòõ).
  • trait-dependent
    Ư¼º-ÀÇÁ¸Àû(÷åàõëîðíîÜ).
  • conditional lethal mutant
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌÁÖ
  • conditional lethal mutation
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌ
  • dose, lethal
    Ä¡»ç·®
  • granuloma, lethal midline
    ¾Ç¼º Á߽ɼ± ¼º À°¾ÆÁ¾
  • half lethal dose
    ¹ÝÄ¡»ç·®(ÚâöÈÞÝåÖ).
  • lethal
    Ä¡»ç
  • lethal coefficient
    Ä¡»ç°è¼ö(ÊÙË­Ëà).
  • lethal concentration
    Ä¡»ç³óµµ
  • lethal dose
    Ä¡»ç¼±·®
  • lethal dose
    Ä¡»ç·®
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minbimum lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝÕá)
  • recessive lethal gene
    ¿­¼º Ä¡»çÀ¯ÀüÀÚ(Ö«àõöÈÞÝë¶îîí­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SCT secretin; sex chromatin test; sexual compatibility test; sickle-cell trait; sperm cytotoxicity; spin...
STAI State Trait Anxiety Inventory
ACD   1) Absolute Cardiac Dullness; Àý´ë½ÉµÐŹÀ½
  2) Anemia of Chronic Disease
&nbs...
AD   1) Alveolar Duct
  2) Autosomal Dominant
  3) Auris Dextra; Ri...
ACHOO autosomal dominant compelling helio-ophthalmic outburst [syndrome]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SCT Sickle cell trait
STAXI State Trait Anger Expression Inventory
STAI State Trait Anxiety Inventory
STAI State and Trait Anxiety Inventory
STAIC State-Trait Anxiety Inventory for Children
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mean lethal dose
    50% Ä¡»ç·®
  • midline lethal granuloma
    Ä¡»ç Á¤Áß À°¾ÆÁ¾
  • autosomal dominant disorder
    »ó¿°»öü ¿ì¼º À¯Àü Áúȯ
  • dominant
    ¿ì¼º, ¿ì¼ºÀÇ
    1. ¿ì¼¼ ¶Ç´Â Áö¹èÀû ¿µÇâÀ» ¹ßÈÖÇÏ´Â. À¯ÀüÇп¡¼­´Â ÇÑ ½ÖÀÌ »óµ¿¿°»öü ÇÑ Âʸ¸À¸·Î ¿î¹ÝµÇ¾îµµ ¹ßÇö °¡´ÉÇÑ. 2. ¿ì¼º ÇüÁú. ¿ì¼º ¼ÒÁú.
  • dominant character
    ¿ì¼º ÇüÁú, Áö¹èÀû Ư¼º
  • dominant cystoid macular dystrophy
    ¿ì¼º ³¶Æ÷ Ȳ¹Ý ÀÌ¿µ¾çÁõ
  • dominant exudative vitreoretinopathy
    ¿ì¼º »ïÃâÀ¯¸®Ã¼ ¸Á¸·º¯Áõ
  • dominant gene
    ¿ì¼º À¯ÀüÀÚ
  • dominant inheritance
    ¿ì¼º À¯Àü
  • dominant receptor
    ¿ì¼º ¼ö¿ëü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
Bombay trait A rare recessive trait at a locus that ordinarily manufactures H substance, the precursor from which the A and B phenotypes are elaborated; the mutant causes failure to produce H substance and no matter what the genotype at the ABO locus, the phenotype is O. The Bombay phenomenon is epistatic to the ABO locus.
Origin: Bombay, India, where first reported
(05 Mar 2000)
galtonian trait A quantitative genetic trait due to contributions from many more of less equally important loci that resembles a continuous trait.
(05 Mar 2000)
recessive trait See: dominance of traits.
(05 Mar 2000)
marker trait A trait that may be of little importance in itself but which by association, linkage, or other means facilitates the detection, anticipation, or understanding of a disease or (for genetic diseases) the localization of the causative gene on the karyotype.
(05 Mar 2000)
categorical trait <genetics> A feature that can conveniently and effectively be analyzed by sorting into classes either because there is no satisfactory way of measuring it (as with blood groups) or because it falls into natural classes so that the variation among classes far exceeds that within classes (e.g., the phenotypic effects of many enzyme polymorphisms); existence of categories suggests but does not prove the operation of a major, simple, underlying cause.
Synonym: qualitative trait.
(05 Mar 2000)
penetrant trait A trait that in the appropriate genotypes is phenotypically manifest; strictly, it is the trait that is penetrant, not the gene.
See: penetrance.
(05 Mar 2000)
mendelian trait A categorical trait that segregates in accordance with a single-locus genetic system.
(05 Mar 2000)
chromosomal trait A trait dependent on a recurrent chromosomal aberration.
(05 Mar 2000)
codominant trait See: codominant.
(05 Mar 2000)
sickle cell trait <haematology> This condition occurs in people who have one of two possible genes (i.e., they are heterozygous forthe allele) that code for the defective haemoglobin responsible for sickle cell anaemia.
The coditionis diagnosed by exposing an individual's red blood cells to a low oxygen environment, if the trait is present, the cells will turn to a sickle shape. People with this trait may suffer milder symptoms of sickle cell anaemia, or may have no symptoms. Some scientists believe the trait actually provides an evolutionary advantage in tropical environments because the slightly altered shape of the blood cells causes a person to be more resistant to malaria.
(09 Oct 1997)
nonpenetrant trait A genetic trait that is not phenotypically manifest because of non-genetic factors it therefore does not include recessivity, epistasis, hypostasis, or parastasis but does include environmental factors and pure random effects such as lyonization.
(05 Mar 2000)
qualitative trait <genetics> A feature that can conveniently and effectively be analyzed by sorting into classes either because there is no satisfactory way of measuring it (as with blood groups) or because it falls into natural classes so that the variation among classes far exceeds that within classes (e.g., the phenotypic effects of many enzyme polymorphisms); existence of categories suggests but does not prove the operation of a major, simple, underlying cause.
Synonym: qualitative trait.
(05 Mar 2000)
quantitative trait A characteristic showing quantitative inheritance such as skin pigmentation in man.
(12 Dec 1998)
intermediate trait A measurable trait in which there is some evidence of the operation of a simple major cause, but in which the variation within the putative categories is such as to cause overlap and hence ambiguity in classification of any particular reading.
(05 Mar 2000)
threshold trait A trait that falls into natural groups that originate not in categorically distinct causes but in whether or not the outcome attains critical values; e.g., gallstones may result from a categorical cause or from unusual levels of causal factors that themselves show no evidence of grouping.
Synonym: liminal trait.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á